EICHORPublic-registry site landscape for NCT04720976, “JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors”, a Solid Tumor study sponsored by Allist Pharmaceuticals, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04720976 (registry record) |
| Study title | JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors |
| Official title | A Phase 1/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult Patients With Advanced Solid Tumors |
| Sponsor | Allist Pharmaceuticals, Inc. |
| Condition(s) | Solid Tumor; NSCLC |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 15 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT04720976.
Eichor generates a preliminary site-risk snapshot for NCT04720976 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Solid Tumor trials
← Eichor home · All tracked trials · Solid Tumor studies · Weekly briefs
